<DOC>
	<DOCNO>NCT00274547</DOCNO>
	<brief_summary>The primary objective trial determine whether treatment tiotropium ( 18 mcg ) capsule daily via HandiHaler reduces proportion patient COPD experience exacerbation proportion patient hospitalize exacerbation six month observation period .</brief_summary>
	<brief_title>Tiotropium ( 18 Mcg ) Once Daily Via HandiHalerÂ® Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>